Target intelligence / Profile preview

Myc proto-oncogene protein (MYC)

Target
MYC
Molecular classification
Transcription factor, Proto-oncogene, Intrinsically disordered protein (IDP)
01

Overview

MYC proto-oncogene protein is a universal transcription factor and proto-oncogene encoded by the human MYC gene[2][5]. It regulates thousands of genes involved in cell growth, division, differentiation, apoptosis, and metabolism, acting as a global amplifier of cellular transcriptional programs[3][4][5]. MYC is among the most frequently activated oncogenic proteins in human cancer, driving unchecked proliferation and immune evasion[2][4]. Structural motifs within MYC mRNA, particularly in the 5' and 3' untranslated regions, can affect gene expression and are being studied as alternative drug targets because the MYC protein itself is highly challenging to inhibit with small molecules[1]. While MYC inactivation results in tumor regression in preclinical models, effective clinical MYC-targeted therapies remain elusive primarily due to safety and targetability concerns[2][1].

Other names
c-MYCMYC oncogeneMyc proto-oncogenev-myc avian myelocytomatosis viral oncogene homolog
02

Mechanism of action

Modulation of gene transcription; Inhibition of MYC/MAX interaction; Destabilization of MYC protein; RNA targeting approaches (antisense oligonucleotides, siRNA, small molecule binders of MYC mRNA motifs)

03

Biological functions

Cell cycle regulationCell proliferationDifferentiationApoptosisSurvivalMetabolismProtein synthesisRibosomal biogenesisImmune response modulation
04

Disease associations

Cancer (most common, especially in neoplasias)Immune evasion
05

Safety considerations

Difficulty in achieving specific, non-toxic targeting due to MYC’s involvement in many essential cellular processes ("undruggable" protein)On-target toxicity: MYC is required in normal cell function, so inhibition can affect normal cell proliferation, hematopoiesis, and tissue renewalOff-target effects from global transcriptional changes
06

Interacting drugs

No approved direct MYC-targeted drugs; several experimental agents targeting MYC protein, MYC/MAX dimerization, or MYC mRNA (e.g., antigene, antisense, siRNA)
07

Biomarkers

MYC amplification (for patient selection in certain cancers)MYC protein or mRNA overexpressionPD-L1/immune checkpoint expression as secondary marker in MYC-driven tumors

Beyond the preview

Go deeper on Myc proto-oncogene protein (MYC).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Myc proto-oncogene protein (MYC).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call